JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M404975200 on May 24, 2004

J. Biol. Chem., Vol. 279, Issue 34, 35858-35866, August 20, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
279/34/35858    most recent
M404975200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chaudhry, H. W.
Right arrow Articles by Wolgemuth, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chaudhry, H. W.
Right arrow Articles by Wolgemuth, D. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cyclin A2 Mediates Cardiomyocyte Mitosis in the Postmitotic Myocardium*

Hina W. Chaudhry{ddagger}§, Nurin H. Dashoush{ddagger}, Haiying Tang¶, Ling Zhang{ddagger}, Xiangyuan Wang||, Ed X. Wu¶¶¶, and Debra J. Wolgemuth||**{ddagger}{ddagger}§§

From the {ddagger}Department of Medicine, the Department of Radiology, the §§Department of Genetics and Development, the ||Department of Obstetrics and Gynecology, **The Center for Reproductive Sciences, and {ddagger}{ddagger}The Institute of Human Nutrition, Columbia University College of Physicians & Surgeons, New York, New York 10032

Received for publication, May 4, 2004 , and in revised form, May 19, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Cell cycle withdrawal limits proliferation of adult mammalian cardiomyocytes. Therefore, the concept of stimulating myocyte mitotic divisions has dramatic implications for cardiomyocyte regeneration and hence, cardiovascular disease. Previous reports describing manipulation of cell cycle proteins have not shown induction of cardiomyocyte mitosis after birth. We now report that cyclin A2, normally silenced in the postnatal heart, induces cardiac enlargement because of cardiomyocyte hyperplasia when constitutively expressed from embryonic day 8 into adulthood. Cardiomyocyte hyperplasia during adulthood was coupled with an increase in cardiomyoctye mitosis, noted in transgenic hearts at all time points examined, particularly during postnatal development. Several stages of mitosis were observed within cardiomyocytes and correlated with the nuclear localization of cyclin A2. Magnetic resonance analysis confirmed cardiac enlargement. These results reveal a previously unrecognized critical role for cyclin A2 in mediating cardiomyocyte mitosis, a role that may significantly impact upon clinical treatment of damaged myocardium.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
It is well established that the proliferative and hence, regenerative potential of adult mammalian cardiomyocytes is quite limited (1). This view has recently been challenged by a few reports, which contend that adult ventricular myocytes, under certain circumstances, appear to re-enter the cell cycle and proliferate (2–4). The potential to reactivate cardiomyocyte proliferation through manipulation of putative cellular regulators or conversion of pluripotent stem cells to cardiac myocytes (5–7) offers an exciting impetus for the design of novel therapeutic interventions to enhance cardiac function during disease conditions. The bulk of evidence maintains, however, that mammalian cardiomyocytes cease to proliferate in the early neonatal period (8–12), which is followed by an increase in cell size. In the murine heart, cardiomyocyte division is reportedly completed by birth, with DNA synthesis through postnatal day 3 contributing only to binucleation (13). The cessation of myocyte proliferation is attributed to an arrest of the cell cycle (14). In accordance with this hypothesis, adult rat cardiomyocytes have been shown to display a dual cell cycle blockade, with ~80% of cells arresting in G0/G1 and 15–20% of cells arresting in G2/M (14–16)

Progression through the cell cycle is tightly regulated and involves cyclins complexed with their catalytic partners, the cyclin-dependent kinases (cdks).1 Among the cyclins, cyclin A2 is unique in that it regulates progression through two critical transitions: cyclin A2 complexed with cdk2 is essential for the G1/S transition and cyclin A2/cdk1 promotes entry into mitosis (17, 18). It is also the only cyclin to be down-regulated at both the message and protein level in rat, human (19), and mouse (the present study) cardiogenesis, coincident with withdrawal of cardiomyocytes from the cell cycle (19). We hypothesized that down-regulation of cyclin A2 may thus play a crucial role in cardiomyocyte cell cycle exit, and conversely, that continued expression of cyclin A2 in the heart would result in altered cell division and importantly, cardiomyocyte hyperplasia.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Generation of Transgenic Mice—Mouse cyclin A2 cDNA was subcloned into a vector (clone 26 from Dr. Jeffrey Robins, University of Cincinnati, Cincinnati, OH) containing {alpha}-myosin heavy chain (MHC) promoter and the human growth hormone polyadenylation site (20). Transgenic mice were then generated according to previous protocols (21). All manipulations were performed according to Institutional Animal Care and Use Guidelines. Pups were screened for the presence of the transgene by genomic DNA blot hybridization (21) using cyclin A2 cDNA as a probe. Six lines of transgenic mice were established on a B6CBA background. Phenotypic characterization in this study was carried out using the F1 generation. All analyses in this study were performed on transgenic mice using nontransgenic littermates as controls.

Assessment of Heart Size/Body Weight Ratios—Each mouse was weighed and then anesthetized with avertin. 3 M KCl was injected into the beating heart to induce diastolic arrest. Hearts were gently perfused with 1x phosphate-buffered saline, and fat tissue was removed before weighing the hearts. Heart to body weight ratios were measured for postnatal day (PN) 7 and 14 and adult (3–18 months).

Assessment of Cell Sizes—Whole ventricular sections from adult (6 months) mice were fixed in 4% paraformaldehyde and embedded in paraffin. Sequential transverse sections (4 µm) were cut and stained with hematoxylin and eosin. Digital pictures were captured at x40 magnification, and cell-analysis software (UTHSCSA Image Tool) was employed to measure cross-sectional areas of myocytes. At least 200 cells/heart were measured for each of two lines (lines 1 and 58). Only cells with clearly delineated borders were measured. Cell lengths were measured utilizing the same program after immunostaining for pancadherin (Sigma), a structural protein found in the intercalated discs (22), again at x40 magnification. Only those myocytes (>200 cells/heart) that could be visualized end-to-end were assessed.

Assessment of Myocyte Number—Ventricles were dissected from 10 transgenic and 10 control hearts and weighed. The average ventricular weight/total heart weight ratio was computed for both transgenic and control hearts and used to compute ventricular weight for the hearts used in measurements of myocyte cross-sectional area and length. Ventricular weight was multiplied by the known value for specific gravity of muscle tissue, 1.06 gm/ml to obtain ventricular volume (23). The calculated ventricular volume was multiplied by 0.82 to determine the fraction occupied by myocytes (24). The average volume of each myocyte was calculated by multiplying myocyte cross-sectional area by length. The number of myocytes per ventricle was computed by dividing the myocyte fraction of ventricular volume by the average myocyte volume.

Northern Blot Analyses—RNA was isolated from total hearts using TriReagent (Sigma). RNA samples (10 µg/lane) were electrophoresed on denaturing 0.8% agarose/2.2 M formaldehyde gels and transferred to nitrocellulose membranes according to standard protocols (25). The 1.7 kb cyclin A2 cDNA (25) was radiolabeled with [{gamma}-32P]UTP and hybridized overnight at 65 °C in 4x SSC, 2x Denhardt's, 0.1% SDS, and 1 mg/ml salmon sperm DNA. Blots were washed at 65 °Cin2x SSC, 0.1% SDS, and signal was visualized by autoradiography at -70 °C. The integrity of RNA samples was established by staining blots with methylene blue (25).

Immunoblot Analyses—Heart tissue was homogenized in tissue lysis buffer, protein lysates were prepared, and immunoblots performed according to standard methods described by Soonpaa et al. (26). Blots were probed with antibodies to cyclin A2 (1:200), cdk2 (1:300), cyclin B1 (1:400), cyclins D2 (1:200), and D3 (1:200), p21 (1:200), p27 (1:100) (Santa Cruz Biotechnology), and cdk1 (1:300, Upstate Biotechnology, Lake Placid, NY). Detection with GAPDH antibody (1:200, Roche Applied Science) was used as a loading control. Subcellular fractionation was performed using the Nuclear Extract kit (Active Motif, Carlsbad, CA). Lamin A/C antibody (1:500, Santa Cruz Biotechnology) was the loading control for nuclear fractions. Signal was visualized by autoradiography using enhanced chemiluminescence according to the manufacturer's protocol (Amersham Biosciences). Autoradiograms were scanned and analyzed by Kodak One-Dimensional Image Analysis software (Eastman Kodak, Rochester, NY). Net intensity values were calculated by subtracting the background within the area measured for each band from the total intensity within this same measured area.

Immune Precipitations—Hearts were homogenized in tissue lysis buffer and processed as above. The following is a modification of Basi and Draetta (27). Homogenate from each sample (250 µg) was preadsorbed with protein A-Sepharose beads (50 µl of a 0.1 mg/ml suspension, Amersham Biosciences) for 1 h at 4 °C. The beads were removed by centrifugation, and the preadsorbed homogenate was reacted with 1 µg of antibody to cyclin A2 in a final volume of 750 µl in tissue lysis buffer. The mixture was incubated with rocking for 1 h at 4 °C. 50 µl of protein A beads were added, and the incubation was continued for an additional 1 h. Immune complexes were collected by centrifugation, washed three times with PBS buffer, and eluted in SDS-PAGE loading buffer containing 1 M N-ethylmaleimide (to limit light chain migration) for 10 min at 95 °C. Samples were resolved on 12% SDS-PAGE gels, electroblotted to nitrocellulose, and subjected to immunoblot analysis as described above with antibodies to cdk1 and cdk2.

Histone H1 Kinase Assays—Preadsorbed tissue homogenate was prepared as above using cdk lysis buffer (16) and reacted with 1 µg of antibody to cyclin A2 with rocking for 1 h at 4 °C. 50 µl of protein A beads were added, and the incubation was continued for an additional 1 h at 4 °C. The immunocomplex beads were washed three times with 1 ml of cdk lysis buffer, then centrifuged, and the pellet was resuspended in 20 µl of wash buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol) containing 125 µg/ml histone H1 substrate protein and incubated for 5 min at 30 °C. To each reaction tube, 5 µl of ATP buffer was added and incubated for 10 min at 30 °C. Samples were resolved on a 12.5% SDS-PAGE gel, the gel was dried, and exposed to x-ray film overnight at -70 °C. Net intensity quantification was performed as described above.

Assessment of Cardiomyocyte DNA Synthesis—Whole ventricular sections from embryonic (E18), postnatal (PN2, PN7, PN14) and adult (6 month) hearts were fixed and embedded in paraffin as described above. Sequential transverse (4 µm) sections were cut and analyzed by immunohistochemistry as described previously (21), using antibody (1:100) to PCNA (BD Pharmingen, San Diego, CA) as an indicator of DNA synthesis (28). To localize PCNA-positive nuclei in cardiomyocytes, co-immunofluorescence (29) staining was performed utilizing {alpha}-sarcomeric actin (1:200, Sigma). Similar fields were compared at x40 magnification, and the number of cardiomyocyte nuclei staining positively for PCNA were counted per field. The total number of cardiomyocyte nuclei per field were counted, and the ratio of PCNA-positive nuclei to the total number of nuclei was computed. This ratio was averaged over at least ten fields to compute the index of PCNA-positive nuclei.

Assessment of Cardiomyocyte Nuclei per Unit Area—Whole ventricular sections from 6-month-old mice from lines 1 and 58 were prepared as above. Immunofluorescence staining (29) with antibody to {alpha}-sarcomeric actin to delineate cardiomyocytes was performed as above. Nuclei were stained with DAPI (Molecular Probes, Eugene, OR). Nuclei within cardiomyocytes were counted for each field (16,800 µm2).

Assessment of Mitosis—Immunofluorescence staining (29) with antibody (1:50) to phosphorylated histone-3 (H3P, Upstate Biotechnology, Lake Placid, NY), a mitosis-specific marker (30), was performed on ventricular sections at various developmental stages. Cardiomyocytes were identified with antibody to {alpha}-sarcomeric actin as above. Antirabbit rhodamine (Molecular Probes, Eugene, OR) was used as the secondary antibody for the H3P antibody, and anti-mouse IgM fluorescein isothiocyanate (Sigma) was used as the secondary against {alpha}-sarcomeric actin. The number of cardiomyocyte nuclei staining positively for H3P were counted per field at x40 magnification under fluorescent field optics. The total number of cardiomyocyte nuclei per field were counted, and a mitotic index was computed as the ratio of H3P-positive nuclei to total nuclei. The mitotic indices for at least ten fields were averaged at each developmental stage analyzed. Rotational analysis for localization to cardiomyocytes was performed using confocal microscopy through 10-micron thick sections.

Isolated Cardiomyocyte Preparations—Isolated ventricular cells were dissociated from hearts obtained from PN7 transgenic and PN7 strain-matched wild-type mice using 0.07% trypsin/1 mM EDTA in Hank's solution, a modification of previously described methods (31). Cells were plated onto microscope slides (after two rounds of pre-plating to minimize fibroblast concentration), fixed with 4% paraformaldehyde, and examined by immunofluorescence staining with antibody (1:200) to {alpha}-sarcomeric actin and DAPI.

Assessment of Cardiac Function—MRI image acquisition and analyses were performed on a 9.4 Tesla Bruker WB400 microimaging system with 30 mm of quadrature RF coil (Brucker NMR Inc., Bellerica, MA). The mice were anesthetized with isoflurane (1.5% vol. in 2 liters/min air flow). The heart rate was ~450 bpm. Quantitation of ventricles was based on bright blood two-dimensional image stacks that were acquired using ECG-gated fast gradient echo cine sequence. The acquisition parameters were 250 ms repetition time, 1.8 ms echo time, 30° flip angle, 0.1 mm in-plane resolution, 1 mm slice thickness, and 4 min/slice scan time. Eight cardiac points were sampled over the cardiac cycle. The short axis images were acquired from which the left ventricle and myocardium was semi-automatically segmented using region-growing algorithm and histogram-based thresholding (32). Data are expressed as mean ± S.E. Student's t test was used for data comparison, using a significance level of p < 0.05.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
To demonstrate that cyclin A2 is silenced in the mouse heart shortly after birth concomitant with withdrawal from mitosis, the relative levels of cyclin A2 mRNA and protein expression were assayed at selected times during murine cardiac development. Northern blot analysis revealed that cyclin A2 transcripts of 3.0 and 1.7 kb were observed at E12, E18, and PN2, but not at 6 weeks of age (Fig. 1A). Immunoblot analysis could not detect cyclin A2 protein at PN2 and later time points (Fig. 1B). The number of ventricular cardiomyocyte nuclei expressing cyclin A2 protein as detected by immunohistochemical analysis was high at E14 with a noticeable decline at E18, a further diminution at PN2, and complete absence by PN14 (Fig. 1C). This temporal pattern of decreased expression of cyclin A2 mRNA and protein levels is consistent with the previously described silencing of cyclin A2 in the hearts of rats and humans shortly after birth (19), and also coincides with cardiomyocyte cell cycle withdrawal (8–12).



View larger version (56K):
[in this window]
[in a new window]
  		FIG. 1.
Cyclin A2 mRNA and protein expression are developmentally regulated in the normal mouse heart. A, cyclin A2 mRNA expression in normal mouse hearts detected by Northern blot: 6 week heart (6wk-H), 6 week kidney (6wk-K), E12 heart (E12-H), E18 heart (E18-H), PN2 heart (PN2-H). Ethidium bromide-stained ribosomal bands are shown as loading controls. B, immunoblot analysis of cyclin A2 protein expression in normal mouse heart: E17.5, PN2, PN7, and 2 months of age. {alpha}-GAPDH antibody was used as loading control. C, cellular localization of cyclin A2 protein expression utilizing immunohistochemistry in ventricular tissue sections from E14 through PN14. The brown staining indicates positively stained cardiomyocyte nuclei

 
To test the hypothesis that sustained cyclin A2 expression would modulate cardiomyocyte proliferation, transgenic mice that constitutively express cyclin A2 in the cardiomyocyte lineage were generated (21). The MHC promoter was chosen because it is expressed from E7.5, throughout embryogenesis, and continues to be expressed through adulthood (20) (Fig. 2A). Eight founders were identified after screening 60 pups derived from microinjected embryos, and six gave rise to transgenic lineages. Cyclin A2 transgenic mice were fertile, appeared healthy, and were not prone to alteration in morbidity and mortality over 1.5 years of observation. Cyclin A2 expression was assessed in at least three hearts from each line at 5–7 months of age by Northern analysis, with a representative blot shown in Fig. 2B. Lines 1, 2, 44, and 58 consistently express the expected cyclin A2 transgenic 2.3 kb mRNA, although there was some variation in the levels of expression from animal to animal within the same line. Other adult organs, such as the kidney (Fig. 2B and data not shown), failed to show cyclin A2 expression in transgenic mice, consistent with the previously described myocardial specificity of the MHC promoter (20). Interestingly, a 3.0-kb band is also visualized in transgenic heart mRNA. This size is consistent with the larger endogenous cyclin A2 transcript and is not seen in control heart mRNA. Cyclin A2 protein expression, assayed by immunoblot analysis, was confirmed in all 4 lines above (data not shown), but line 58 was selected for more detailed analysis. Cyclin A2 protein expression is shown in transgenic hearts from line 58 at ages PN14 and 2 months and is absent in control hearts at both time points (Fig. 2C).



View larger version (50K):
[in this window]
[in a new window]
  		FIG. 2.
Transgenic mouse model constitutively expressing cyclin A2. A, diagram of MHC-CYCA2 transgenic construct. B, representative Northern blot analysis of transgenic mice (t23 and t27) and control mice (n1 and n2). H and K indicate heart and kidney, respectively. Blot was re-exposed for a shorter period of time to delineate detail in the t23-H lane. Ethidium bromide-stained ribosomal bands are shown as loading controls. C, immunoblot analysis of cyclin A2, cdk1 and cdk2 with GAPDH as loading control in transgenic (Tg) and non-transgenic (N) hearts at PN14 and 2 months of age. HeLa lysate was the positive control. D, subcellular localization of cyclin A2 protein in Tg and N hearts at PN7 and PN14 utilizing nuclear and cytoplasmic protein extracts. GAPDH is the loading control for cytoplasm, whereas Lamin A/C is the loading control for nuclear extracts. E, immunoprecipitation of cyclin A2 complexes in Tg and N hearts at PN14, and 2-month {alpha}-cyclin A2-immunoprecipitated complexes were analyzed by immunoblot with {alpha}-cdk1 or {alpha}-cdk2. HeLa cell lysate was the positive control. F, H1 histone kinase assay of Tg and N heart protein lysates from PN7, PN14, and 2-month NC represents negative control (lysis buffer with no sample), and thymus is the positive control. G, subcellular localization of cyclin B1 protein in Tg and N hearts at PN7 utilizing nuclear and cytoplasmic protein extracts with GAPDH and Lamin A/C controls as described in two dimensions. H, immunoprecipitation of cdk1/cyclin B1 complexes in Tg and N hearts at PN7. {alpha}-Cdk1-immunoprecipitated complexes were analyzed by immunoblot with {alpha}-cyclin B1 with HeLa lysate as positive control. I and J, immunoblot analysis of p21 and p27 expression in Tg and N heart protein lysates from PN7, PN14, and 2 months of age. K, immunoblot analyses of cyclin D2 and D3 expression in Tg and N hearts.

 
To determine if the continued expression of cyclin A2 altered the expression of cdk1 and cdk2, lysates were analyzed by immunoblot analysis (Fig. 2C). An average 1.6-fold and 1.2-fold increase in the levels of cdk1 protein at PN14 and 2 months, respectively, were observed in total transgenic hearts, notably different from the low levels of constitutive expression of cdk1 in controls. Immunoblot analysis demonstrated low levels of expression of cdk2 in control hearts, consistent with studies by others (33). Interestingly, an average 2.5- and 2.1-fold increase in the expression of cdk2 in transgenic hearts was observed at PN14 and 2 months of age, respectively.

To determine the subcellular distribution of cyclin A2 protein, lysates were prepared from nuclear and cytoplasmic fractions at PN7 and PN14. In transgenic hearts, cyclin A2 was noted to be predominantly localized to the nucleus at PN7, but largely in cytoplasm by PN14 (Fig. 2D). No protein was detected in either the nucleus or cytoplasm in control hearts at PN7 or PN14 (Fig. 2D).

To determine whether this temporally ectopically expressed cyclin A2 actually complexed with its normal cdk1 or cdk2 partner, immunoprecipitation followed by immunoblot analysis was performed using total heart lysates (Fig. 2E). Both cyclin A2-cdk1 and cyclin A2-cdk2 complexes were clearly detected at PN14 in transgenic hearts but never in controls. Cyclin A2-cdk2 complex was still detected at 2 months in transgenic hearts but not in controls. To assess the activity of these complexes, {alpha}-cyclin A2 immunoprecipitates were also assayed for histone H1 kinase activity. Histone H1 kinase activity was higher in transgenic hearts at PN7, PN14, and 2 months. At PN14, it was 2.0-fold higher as averaged over three independent assays performed at this stage (Fig. 2F).

Potential alterations in the expression profiles of other cell cycle regulators in response to deregulated cyclin A2 were explored. Interestingly, subcellular fractionation revealed that cyclin B1, the only other mitotic cyclin, was expressed in nuclear extracts of PN7 transgenic hearts in a more robust manner than in cytoplasmic extracts, whereas in the controls, cyclin B1 was detectable only in cytoplasmic extracts (Fig. 2G). Comparable amounts of cdk1-cyclin B1 complexes were noted in both transgenic and control heart protein extracts at PN7 and PN14 (Fig. 2H). There was no change in the levels of the cdk inhibitor p21 in transgenic versus control hearts at all stages examined (Fig. 2I). However, p27 was significantly up-regulated (Fig. 2J, average for three immunoblots: 2.97-fold at PN7, 1.55-fold at PN14, and 1.48-fold at 2 months). Cyclins D2 and D3 were also found to be up-regulated in transgenic hearts at PN14 and 2 months of age as compared with controls (Fig. 2K).

No gross morphological abnormalities were noted in the transgenic hearts. However, the heart weight to body weight ratio (HW/BW) of adult transgenic mice was significantly increased when compared with controls across lines (1, 2, 44, and 58) that expressed cyclin A2 mRNA. A closer analysis of this phenotype was undertaken in lines 1 and 58. HW/BW ratios were determined at selected ages from post-natal development through adulthood, beginning at PN7 up to 1.5 years of age. There was no significant cardiac enlargement noted at PN7 and PN14 (Fig. 3A). However, the difference between the HW/BW ratios of transgenic versus controls increased with age, with statistical significance noted ≥6 months of age.



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 3.
Cyclin A2 transgenic mice exhibit cardiac hyperplasia due to an increase in postnatal mitosis. A, heart enlargement in cyclin A2 transgenic mice. HW/BW ratios (mg/g) of Normal and Transgenic mice were plotted from PN7 through 1.5 years of age. The numbers of Tg and N mice examined at each age are detailed as follows: PN7 and PN14, 16 Tg, 15 N; 3–4mo., 5 Tg, 5 N; 6mo., 10 Tg, 10 N; 8–12mo., 5 Tg, 5 N; 1.5 yr.,1Tg,1N. Asterisks indicate ages at which the HW/BW difference between Tg and N is statistically significant. B, myocyte cross-sectional areas were measured in N versus Tg ventricles (lines 1 and 58, age 6 months) using hematoxylin and eosin-stained sections. C, myocyte lengths measured in N versus Tg (Line 1 and 58, age 6 months) using Pan-cadherin staining. D, PCNA expression in N and Tg hearts at selected time points through development. E, isolated ventricular myocytes at PN7 demonstrate a predominantly mononuclear phenotype in the transgenic hearts. F, detection of H3P in N and Tg myocardium at selected time points through development.

 
Microarray magnetic resonance imaging (MRI) analysis is the most technologically advanced modality for assessing cardiac mass and function, and is the most accurate and reliable method for noninvasively quantifying left ventricular mass and function in mice (34, 35). MRI images at end-diastole at midventricular level were therefore utilized for the assessment of cardiac size in transgenic and gender-matched controls in line 58 at 8 months of age. The transgenic (n = 3) mouse hearts occupied an average of 41.0 + 0.01% of the chest area compared with 30.5 + 0.01% by the controls (n = 3, p = 0.0083). The MRI analysis thus confirmed in living hearts that the area of the chest cavity occupied by the heart is larger in the transgenic mice. Staining with Masson trichrome revealed no evidence of increased fibrosis in the transgenic hearts at 6 months of age (data not shown), suggesting that an increase in connective tissue did not contribute to increased cardiac size.

To determine if the continued expression of cyclin A2 resulted in hyperplasia, which would contribute to the enlarged heart phenotype, we calculated the total number of ventricular cardiomyocytes present in hearts from lines 1 and 58 at 6 months of age. The first step was to measure myocyte cross-sectional areas and length (Fig. 3, B and C). Myocyte cross-sectional areas were in fact slightly reduced in transgenic hearts (average of 209.7 + 2.32 µm2 versus 228.2 + 2.29 µm2 in line 1, p < 0.0001). In line 58, there was an average cross-sectional area of 193.2 + 2.04 µm2 in transgenic versus 231.0 + 2.26 µm2, p < 0.0001. Myocyte length was found to be shorter in transgenic hearts with an average length of 48.4 + 0.599 µm in line 1 transgenic versus 51.9 + 0.583 µm, p < 0.0001. In line 58, there was an average length of 46.2 + 0.522 µm in transgenic versus 50.2 + 0.567 µm, p < 0.0001.

The measurements of cardiomyocyte cross-sectional area and length were utilized to calculate the average myocyte volume in representative hearts from line 1 and 58 in which the original measurements were made (Table I). The quotient of the total ventricular volume and average myocyte volume gave an estimate of the number of myocytes present in each ventricle. At 6 months of age, there was an average increase of 67.3 and 43.4% in the number of ventricular myocytes present in line 58 and line 1 transgenic hearts respectively, as compared with age-matched controls. The slight reduction in cardiomyocyte size in the transgenic mouse heart coupled with the overall increase in cardiac size demonstrates that constitutive expression of cyclin A2 elicits cardiomyocyte hyperplasia.


View this table:
[in this window]
[in a new window]
  		TABLE I
Ventricular myocyte number in transgenic versus normal hearts Average myocyte volume in representative hearts from Line 1 and Line 58 was calculated utilizing measurements from myocyte cross-sectional areas and lengths. The number of myocytes per ventricle was calculated as the quotient of myocyte fraction of ventricular volume and average myocyte volume.

 
As hyperplasia should be coupled with an increase in cell division, we assayed DNA synthesis in cardiomyocyte nuclei (28), as reflected by the expression of proliferating cell nuclear antigen (PCNA). The fraction of PCNA-stained nuclei to total nuclei in lines 1 and 58 was similar in transgenics and controls through E18, but by PN2, there was a markedly higher level of expression in transgenic hearts (Fig. 3D). This elevation in PCNA expression persisted to 6 months of age, albeit at more modest levels, while PCNA expression is virtually undetected in control hearts. These results suggested that cyclin A2 expression was correlated with an increase in DNA synthesis.

The increase in DNA synthesis could simply reflect increased multinucleation of transgenic myocytes. To examine this possibility, isolated cardiomyocyte preparations were made from transgenic hearts of line 58 at PN7. Nuclei per cell were counted, and 339 cells were examined. The majority of cardiomyocytes at this stage were found to be mononuclear 84.6% mononuclear, 14.7% binuclear, and 0.70% trinuclear (Fig. 3E). It has previously been demonstrated that most cardiomyocytes in the wild-type developing mouse heart undergo binucleation by PN3 (13). Our own results confirm that strain-matched wild-type cardiomyocytes at PN7 are overwhelmingly binucleated or trinucleated (data not shown).

Cardiomyocyte nuclear density was measured by counting nuclei per unit area in transverse sections from adult (6 months, lines 1 and 58) ventricular myocardium. Cardiomyocytes were identified by staining with an antibody to {alpha}-sarcomeric actin, and DAPI was used to highlight nuclei. There was no significant change in the number of cardiomyocyte nuclei per unit area in transgenics versus controls for both lines 1 and 58, 32.70 + 1.86 versus 31.60 + 1.80, respectively. Corresponding numbers for line 58 are 30.60 + 1.76 versus 32.20 + 2.05. These data further support the conclusion that increased DNA synthesis in transgenic hearts results in myocyte hyperplasia.

As cyclin A2 regulates progression through the G2/M transition in addition to the G1/S checkpoint of the cell cycle, we sought to determine whether there was an increase in cardiomyocyte mitoses in our transgenic model utilizing an anti-phosphohistone-3 antibody. H3P on Ser10 is an established marker for chromosome condensation during mitotic prophase in animal cells (30). Histologic sections of hearts at various developmental stages were co-stained with antibodies to {alpha}-sarcomeric actin (to identify cardiomyocytes) and H3P. There was a significant increase in the mitotic index (ratio of H3P-positive cardiomyocyte nuclei to total cardiomyocyte nuclei) noted throughout all developmental time points examined (E18, PN2, PN7, PN14, and 6 months) in transgenic hearts (line 58, Fig. 3F). This analysis was repeated in line 1 for E18, PN7, and PN14 with similar results (data not shown). The data from the 6-month time point are not shown because there were only a few scattered mitoses noted in transgenic hearts, and none were noted in controls. The most dramatic elevation in the mitotic index in transgenic hearts was noted at PN7 at which time there was a 5-fold increase in the mitotic index.

Images obtained using confocal microscopy (similar ventricular sections of PN7 N in Fig. 4A and Tg in Fig. 4B) illustrate several stages of mitosis-prophase, prometaphase, and likely anaphase in transgenic cardiomyocytes (Fig. 4, C–E). Rotational analysis of a 10 micron-thick histologic section further illustrated the presence of a mitotic prometaphase nucleus within an {alpha}-sarcomeric actin-stained cardiomyocyte (see Supplemental Data).



View larger version (94K):
[in this window]
[in a new window]
  		FIG. 4.
Visualization of mitotic nuclei in ventricular myocardium from PN7 N and Tg mice. A and B, H3P staining (red) and sarcomeric actin (green). Different stages of mitosis are observed in cardiomyocytes. C, prophase; D, prometaphase; E, likely anaphase.

 
Cardiac function analysis was undertaken in transgenic (n = 3) and nontransgenic littermate controls (n = 3) from line 58 males at 8 months of age utilizing MRI (Fig. 5, A and B; also see Supplemental Data). Ejection fraction was computed from the difference between the end-diastolic cavity area and the endsystolic cavity area at mid-ventricular level. Fractional shortening was assessed by measuring thickening of the endocardium during systole (Fig. 5C). There was a mild, but statistically significant decrease in both ejection fraction and fractional shortening in the transgenic hearts compared with their littermate control hearts at this time point. Echocardiographic analysis at an earlier time point (3 months of age) was performed among 3 lines (1, 2, and 58) for transgenic (n = 6) and control (n = 6) mice, and there was no difference observed in fractional shortening (data not shown).



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 5.
MRI analysis of cardiac function. A, MRI image of transgenic heart at mid-ventricular cross-section of 8-month-old Tg mouse. B, MRI images at mid-ventricular cross-section taken at different points in the cardiac cycle for the measurement of ejection fraction and fractional shortening. Ventricle in red indicates end-diastole and ventricle in yellow indicates end-systole. C, ejection fraction and fractional shortening as calculated from MRI analysis for N (n = 3) and Tg (n = 3) hearts.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
One possible approach to cardiac regeneration involves manipulation of cellular proteins to promote cell cycle re-entry and proliferation of cardiomyocytes. This approach has received considerable interest in recent years because of the identification of key cell cycle regulatory proteins and several reports suggesting that manipulation of these factors can reactivate DNA synthesis in vivo and in vitro in the postmitotic ventricular myocardium (36–38). However, previous reports have not directly demonstrated that regulation of these factors can induce cardiomyocyte mitosis once the time line for cell cycle exit and thus terminal differentiation has been surpassed.

A significant gap in our understanding of the cardiomyocyte cell cycle is due to the limited number of studies that explore the effects of putative cellular regulators of the G2/M checkpoint. Cyclin A2 is unique among all cyclins in that it has been shown to regulate transition through both G1/S and G2/M in cultured cell lines (17). Cyclin A2 is normally silenced in the heart shortly after birth when cardiomyocyte division ceases as the cells withdraw from the cell cycle. This was previously established in rat and human hearts (19), and we have confirmed this in the mouse. The temporal pattern of cyclin A2 mRNA and protein levels implicates a crucial role for cyclin A2 as a regulator of cardiomyocyte cell cycle exit. A recent report describing the effect of inhibiting the Rho family GTPases lends further support to the association of cyclin A2 and cardiomyocyte proliferation (39). That is expression of Rho GDI{alpha}, an inhibitor of Rho family proteins, in the mouse myocardium resulted in a decrease in cellular proliferation in the embryonic heart that was associated with down-regulation of cyclin A2.

To test the impact of its deregulated expression on cardiomyocyte proliferation and terminal differentiation, we have generated a mouse model of constitutive cyclin A2 expression in the myocardium. Phenotypic analysis reveals cardiac enlargement in the adult heart due to hyperplasia. Importantly, cardiomyocyte mitoses were significantly enhanced during postnatal development in the transgenic hearts, with the most dramatic difference occurring at PN7. The hyperplasia induced by constitutive cyclin A2 expression arises largely during postnatal development and not primarily during embryogenesis, as is likely the case in several other mouse models of altered or absent cell cycle proteins. Liao et al. (40) noted that cardiac overexpression of cdk2 elicited heart enlargement at PN2 but this did not persist in adults. c-Myc-overexpressing mice exhibited an enlargement in cardiac size that was most profound at 1 and 15 days of age (44 and 46%, respectively), but by 60 days of age, only a 34% increase was noted (24). The investigators concluded that this hyperplasia occurred during fetal development without acceleration of postnatal growth. The p27KIPI knockout mice exhibited a significant increase in heart weight when compared with wild type as analyzed between 2 and 35 days of age (41). Interestingly, we note elevated levels of p27KIPI in our transgenic mouse hearts, alluding to a feedback mechanism whereby p27KIPI regulates cyclin A2 levels in the cardiomyocyte, but p21CIP1 does not.

Cyclin D1 overexpression in the mouse heart has been shown to promote increased DNA synthesis in adult transgenic hearts that resulted in multinucleation, but mitosis was not examined (26). Approximately 40% enlargement was noted when the HW/BW ratios of adult transgenic mice were compared with those of nontransgenic mice (n = 4, age not specified). Although >60% of the adult cyclin D1 transgenic cardiomyocytes exhibited a multinucleated phenotype, the authors concluded that it was unclear whether these cardiomyocytes retained the ability to undergo karyokinesis. This same group of investigators had previously demonstrated that cardiomyocyte division in the normal mouse heart does not occur after birth, with DNA synthesis through PN2 and PN3 contributing only to binucleation (13).

As cyclin A2 has been shown to regulate both G1/S and G2/M in cultured mammalian cell lines (17), we presume it is playing a role in the regulation of both gap phases in vivo. In Drosophila, when regulators of both gap phases are overproduced (i.e. cyclin E and string), cells are unable to compensate for the shortening of both gap phases and the cell cycle as a whole is abbreviated, resulting in small cells with a faster generation time (42). Previous investigators have demonstrated that overexpression of G1- to S-phase cell cycle regulatory proteins decreased cell size in vitro and in vivo (40, 43). This mechanism may account in part for the cardiomyocyte hyperplasia, with smaller cells noted in our model. Although an overall increase in heart size is not observed until the increased numbers of cardiomyocytes found in the postnatal hearts begin to grow, the most dramatic effect of "de-silencing" cyclin A2 occurs after birth, when cardiogenesis is normally complete.

Functional analysis indicated preservation of cardiac function at 3 months of age with a decline in ejection fraction and fractional shortening noted at 8 months of age in the transgenic hearts. This is also consistent with the observation of greater HW/BW differences between transgenic and normal after 5–6 months of age as compared with younger animals. Hyperplastic hearts would be expected to display hypercontractility that would ultimately progress to hypocontractility with age.

In conclusion, constitutive cardiac expression of normally silent cyclin A2 invokes an increase in cardiomyocyte mitosis and hyperplasia in the postnatal heart with resultant cardiac enlargement noted in the adult heart. This model differs from previous mouse models examining altered or absent cell cycle regulators in that it specifically addresses control of the G2/M checkpoint in addition to the G1/S checkpoint. Furthermore, karyokinesis in postnatal cardiomyocytes is specifically demonstrated. The enhanced HW/BW increase in the transgenic heart compared with normal during adulthood suggests that cytokinesis is indeed coupled with mitosis in the transgenic heart. The decline of cardiomyocyte mitoses noted between PN7 and PN14 with only scattered mitoses noted in the adult heart also correlated with a change in the subcellular localization of cyclin A2. The nuclear localization of cyclin A2 appeared to be critical for cardiomyocyte mitosis. Nuclear expression of cyclin A2 further appears to induce nuclear localization of cyclin B1, which normally is detected only in the cytoplasm after birth. Constitutive expression of cyclin A2 also increased expression of the D-type cyclins, further highlighting a master regulatory role for cyclin A2 in the cardiomyocyte cell cycle. The manipulation of cyclin A2 expression to induce cardiac mitosis, and thus hyperplasia, should serve as a nidus for future studies examining therapeutic application by gene delivery of cyclin A2 to the infarcted, postmitotic myocardium.


   FOOTNOTES
 
* This work was supported in part by grants from the American Heart Association (to H. W. C.) and the National Institutes of Health (to H. W. C. and D. J. W.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

The on-line version of this article (available at http://www.jbc.org) contains Supplemental Data. Back

¶¶ Present address: Dept. of Electrical and Electronics Engineering, University of Hong Kong, Hong Kong, China. Back

§ To whom correspondence should be addressed: Dept. of Medicine, Columbia University College of Physicians & Surgeons, 622 W. 168th St., New York, NY 10032. Tel.: 212-305-2253; Fax: 212-305-6084; E-mail: hwc7{at}columbia.edu.

1 The abbreviations used are: cdk, cyclin-dependent kinase; DAPI, 4',6-diamidino-2-phenylindole; MHC, {alpha}-myosin heavy chain; PN, postnatal day; E, embryonic day; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; H3P, phosphorylated histone-3; N, non-transgenic; Tg, transgenic; HW/BW, heart weight to body weight ratio. Back


   ACKNOWLEDGMENTS
 
We thank Drs. Laura Johnston and Jeffrey Holmes for discussions and suggestions related to phenotypic characterization, Dr. Jeffrey Robbins for the {alpha}-MHC promoter construct, Dr. Richard Vallee for his insights into the stages of mitosis, and Theresa Swayne and the Confocal Microscopy Facility at Columbia Health Sciences for their assistance with confocal analyses.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Rumyantsev, P. P. (1991) Growth and Hyperplasia of Cardiac Muscle Cells, Harwood Academic Publishers, New York
  2. Leri, A., Malhotra, A., Liew, C. C., Kajstura, J., and Anversa, P. (2000) J. Mol. Cell Cardiol 32, 385-390[CrossRef][Medline] [Order article via Infotrieve]
  3. Kajstura, J., Pertoldi, B., Leri, A., Beltrami, C. A., Deptala, A., Darzynkiewicz, Z., and Anversa, P. (2000) Am. J. Pathol. 156, 813-819[Abstract/Free Full Text]
  4. Beltrami, A. P., Urbanek, K., Kajstura, J., Yan, S. M., Finato, N., Bussani, R., Nadal-Ginard, B., Silvestri, F., Leri, A., Beltrami, C. A., and Anversa, P. (2001) N. Engl. J. Med. 344, 1750-1757[Abstract/Free Full Text]
  5. Orlic, D., Kajstura, J., Chimenti, S., Jakoniuk, I., Anderson, S. M., Li, B., Pickel, J., McKay, R., Nadal-Ginard, B., Bodine, D. M., Leri, A., and Anversa, P. (2001) Nature 410, 701-705[CrossRef][Medline] [Order article via Infotrieve]
  6. Oh, H., Bradfute, S. B., Gallardo, T. D., Nakamura, T., Gaussin, V., Mishina, Y., Pocius, J., Michael, L. H., Behringer, R. R., Garry, D. J., Entman, M. L., and Schneider, M. D. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 12313-12318[Abstract/Free Full Text]
  7. Jackson, K. A., Majka, S. M., Wang, H., Pocius, J., Hartley, C. J., Majesky, M. W., Entman, M. L., Michael, L. H., Hirschi, K. K., and Goodell, M. A. (2001) J. Clin. Investig. 107, 1395-1402[CrossRef][Medline] [Order article via Infotrieve]
  8. Beinlich, C. J., and Morgan, H. E. (1993) Mol. Cell Biochem. 119, 3-9[CrossRef][Medline] [Order article via Infotrieve]
  9. Casscells, W., Speir, E., Sasse, J., Klagsbrun, M., Allen, P., Lee, M., Calvo, B., Chiba, M., Haggroth, L., Folkman, J., and Epstein, S. (1990) J. Clin. Investig. 85, 433-441[Medline] [Order article via Infotrieve]
  10. Speir, E., Tanner, V., Gonzalez, A. M., Farris, J., Baird, A., and Casscells, W. (1992) Circ. Res. 71, 251-259[Abstract/Free Full Text]
  11. Parker, T. G., and Schneider, M. D. (1991) Annu. Rev. Physiol. 53, 179-200[Medline] [Order article via Infotrieve]
  12. Simpson, P. C. (1989) Annu. Rev. Physiol. 51, 189-202[CrossRef][Medline] [Order article via Infotrieve]
  13. Soonpaa, M. H., Kim, K. K., Pajak, L., Franklin, M., and Field, L. J. (1996) Am. J. Physiol. 271, H2183-H2189[Medline] [Order article via Infotrieve]
  14. Brooks, G., Poolman, R. A., and Li, J. M. (1998) Cardiovasc. Res. 39, 301-311[Abstract/Free Full Text]
  15. Poolman, R. A., Gilchrist, R., and Brooks, G. (1998) Int. J. Cardiol. 67, 133-142[CrossRef][Medline] [Order article via Infotrieve]
  16. Brooks, G., Poolman, R. A., McGill, C. J., and Li, J. M. (1997) J. Mol. Cell Cardiol. 29, 2261-2271[CrossRef][Medline] [Order article via Infotrieve]
  17. Sherr, C. J., and Roberts, J. M. (1995) Genes Dev. 9, 1149-1163[Free Full Text]
  18. Pagano, M., Pepperkok, R., Verde, F., Ansorge, W., and Draetta, G. (1992) EMBO J. 11, 961-971[Medline] [Order article via Infotrieve]
  19. Yoshizumi, M., Lee, W. S., Hsieh, C. M., Tsai, J. C., Li, J., Perrella, M. A., Patterson, C., Endege, W. O., Schlegel, R., and Lee, M. E. (1995) J. Clin. Investig. 95, 2275-2280[Medline] [Order article via Infotrieve]
  20. Subramaniam, A., Jones, W. K., Gulick, J., Wert, S., Neumann, J., and Robbins, J. (1991) J. Biol. Chem. 266, 24613-24620[Abstract/Free Full Text]
  21. Behringer, R. R., Crotty, D. A., Tennyson, V. M., Brinster, R. L., Palmiter, R. D., and Wolgemuth, D. J. (1993) Development 117, 823-833[Abstract]
  22. Bianchi, C., Araujo, E. G., Sato, K., and Sellke, F. W. (2001) Circulation 104, I319-I324[Medline] [Order article via Infotrieve]
  23. Mendez, J., and Keys, A. (1960) Metabolism 9, 184-188
  24. Jackson, T., Allard, M. F., Sreenan, C. M., Doss, L. K., Bishop, S. P., and Swain, J. L. (1990) Mol. Cell. Biol. 10, 3709-3716[Abstract/Free Full Text]
  25. Ravnik, S. E., and Wolgemuth, D. J. (1996) Dev. Biol. 173, 69-78[CrossRef][Medline] [Order article via Infotrieve]
  26. Soonpaa, M. H., Koh, G. Y., Pajak, L., Jing, S., Wang, H., Franklin, M. T., Kim, K. K., and Field, L. J. (1997) J. Clin. Investig. 99, 2644-2654[Medline] [Order article via Infotrieve]
  27. Basi, G., and Draetta, G. (1995) Mol. Cell. Biol. 15, 2028-2036[Abstract]
  28. Haracska, L., Unk, I., Johnson, R. E., Phillips, B. B., Hurwitz, J., Prakash, L., and Prakash, S. (2002) Mol. Cell. Biol. 22, 784-791[Abstract/Free Full Text]
  29. Liao, C., Wang, X. Y., Wei, H. Q., Li, S. Q., Merghoub, T., Pandolfi, P. P., and Wolgemuth, D. J. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 6853-6858[Abstract/Free Full Text]
  30. Wei, Y., Mizzen, C. A., Cook, R. G., Gorovsky, M. A., and Allis, C. D. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7480-7484[Abstract/Free Full Text]
  31. Reinecke, H., Zhang, M., Bartosek, T., and Murry, C. E. (1999) Circulation 100, 193-202[Abstract/Free Full Text]
  32. Tang, H., Vasselli, J., Wu, E., and Gallagher, D. (2000) Ann. N. Y. Acad. Sci. 904, 32-41[Abstract/Free Full Text]
  33. Oh, H., Taffet, G. E., Youker, K. A., Entman, M. L., Overbeek, P. A., Michael, L. H., and Schneider, M. D. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 10308-10313[Abstract/Free Full Text]
  34. Wiesmann, F., Ruff, J., Hiller, K. H., Rommel, E., Haase, A., and Neubauer, S. (2000) Am. J. Physiol. Heart Circ Physiol 278, H652-657[Abstract/Free Full Text]
  35. Slawson, S. E., Roman, B. B., Williams, D. S., and Koretsky, A. P. (1998) Magn. Reson. Med. 39, 980-987[Medline] [Order article via Infotrieve]
  36. Kirshenbaum, L. A., and Schneider, M. D. (1995) J. Biol. Chem. 270, 7791-7794[Abstract/Free Full Text]
  37. Agah, R., Kirshenbaum, L. A., Abdellatif, M., Truong, L. D., Chakraborty, S., Michael, L. H., and Schneider, M. D. (1997) J. Clin. Investig. 100, 2722-2728[Medline] [Order article via Infotrieve]
  38. Soonpaa, M. H., and Field, L. J. (1998) Circ. Res. 83, 15-26[Free Full Text]
  39. Wei, L., Imanaka-Yoshida, K., Wang, L., Zhan, S., Schneider, M. D., DeMayo, F. J., and Schwartz, R. J. (2002) Development 129, 1705-1714[Abstract/Free Full Text]
  40. Liao, H. S., Kang, P. M., Nagashima, H., Yamasaki, N., Usheva, A., Ding, B., Lorell, B. H., and Izumo, S. (2001) Circ. Res. 88, 443-450[Abstract/Free Full Text]
  41. Poolman, R. A., Li, J. M., Durand, B., and Brooks, G. (1999) Circ. Res. 85, 117-127[Abstract/Free Full Text]
  42. Neufeld, T. P., de la Cruz, A. F., Johnston, L. A., and Edgar, B. A. (1998) Cell 93, 1183-1193[CrossRef][Medline] [Order article via Infotrieve]
  43. Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J. Y., Bar-Sagi, D., Roussel, M. F., and Sherr, C. J. (1993) Genes Dev. 7, 1559-1571[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
W.-J. Song, W. E. Schreiber, E. Zhong, F.-F. Liu, B. D. Kornfeld, F. E. Wondisford, and M. A. Hussain
Exendin-4 Stimulation of Cyclin A2 in {beta}-Cell Proliferation
Diabetes, September 1, 2008; 57(9): 2371 - 2381.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Tamamori-Adachi, H. Takagi, K. Hashimoto, K. Goto, T. Hidaka, U. Koshimizu, K. Yamada, I. Goto, Y. Maejima, M. Isobe, et al.
Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and Skp2 ubiquitin ligase
Cardiovasc Res, July 24, 2008; (2008) cvn183v2.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
S. Siddiqi, N. Gude, T. Hosoda, J. Muraski, M. Rubio, G. Emmanuel, J. Fransioli, S. Vitale, C. Parolin, D. D'Amario, et al.
Myocardial Induction of Nucleostemin in Response to Postnatal Growth and Pathological Challenge
Circ. Res., July 3, 2008; 103(1): 89 - 97.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. J. Hassink, K. B. Pasumarthi, H. Nakajima, M. Rubart, M. H. Soonpaa, A. B. de la Riviere, P. A. Doevendans, and L. J. Field
Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction
Cardiovasc Res, April 1, 2008; 78(1): 18 - 25.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Q. Li, Y. Guo, W. Tan, Q. Ou, W.-J. Wu, D. Sturza, B. Dawn, G. Hunt, C. Cui, and R. Bolli
Cardioprotection Afforded by Inducible Nitric Oxide Synthase Gene Therapy Is Mediated by Cyclooxygenase-2 via a Nuclear Factor-{kappa}B Dependent Pathway
Circulation, October 2, 2007; 116(14): 1577 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
R. K. Cheng, T. Asai, H. Tang, N. H. Dashoush, R. J. Kara, K. D. Costa, Y. Naka, E. X. Wu, D. J. Wolgemuth, and H. W. Chaudhry
Cyclin A2 Induces Cardiac Regeneration After Myocardial Infarction and Prevents Heart Failure
Circ. Res., June 22, 2007; 100(12): 1741 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
Y. J. Woo, C. M. Panlilio, R. K. Cheng, G. P. Liao, E. E. Suarez, P. Atluri, and H. W. Chaudhry
Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2
J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 927 - 933.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
P. Ahuja, P. Sdek, and W. R. MacLellan
Cardiac Myocyte Cell Cycle Control in Development, Disease, and Regeneration
Physiol Rev, April 1, 2007; 87(2): 521 - 544.